ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -42 مورد

Potential benefits of hydroxyurea in individuals with sickle cell disease

Potential benefits of hydroxyurea in individuals with sickle cell disease
Potential benefit Comments
Improved survival and increased life expectancy
  • Especially useful in reducing death from pulmonary complications including ACS and pulmonary hypertension
  • Longer duration of therapy associated with cumulative benefit
Decreased vaso-occlusive pain
  • Applies to infants, children, and adults
  • Can reduce the number of episodes by 50% or more
  • In turn reduces hospitalizations
Decreased ACS episodes
  • Applies to infants, children, and adults
  • Can reduce the number of episodes (including visits to the emergency department and hospital admissions) by 50% or more
Decreased transfusions
  • Reduces transfusion complications including alloimmunization, transfusion reactions, and iron overload
Decreased TCD measurements
  • Correlates with reduced risk of stroke
  • Generally applies to children and adolescents
  • Regular transfusions are initial treatment for elevated TCD
Decreased priapism episodes
  • Indirect evidence, mostly from small observational studies
Improved quality of life and daily functioning
  • Involves multiple benefits such as those listed above
  • May translate to fewer hospitalizations, better school attendance, and fewer days lost from work
Improved disease markers
  • Increased cerebral oxygen saturation
  • Increased fetal hemoglobin (decreased percent Hb S)
  • Increased total hemoglobin (decreased severity of anemia)
  • Improved hemoglobin-oxygen saturation
  • Improved markers kidney function
  • Improved markers of cardiac and pulmonary disease
  • Reduced hemolysis
  • Decreased WBC count and neutrophil count
Hydroxyurea can be administered at any age, from infants age 6 months to adults, in any region of the world. It is discontinued 3 months before attempted conception and during pregnancy. Benefits are greatest in individuals with Hb SS or Hb S-beta0-thalassemia, but many individuals with Hb SC disease receive similar benefits. Refer to UpToDate for a discussion of the indications for hydroxyurea, alternative options for disease-modifying therapies, an approach to initiating and monitoring hydroxyurea, supporting evidence for efficacy, and potential adverse effects.
ACS: acute chest syndrome; Hb: hemoglobin; HU: hydroxyurea; SCD: sickle cell disease; TCD: transcranial Doppler; WBC: white blood cell.
Graphic 129652 Version 4.0